Loma Linda, California 92350

  • Urinary Tract Diseases

Purpose:

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.


Study summary:

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. Subjects of prospective study will be randomly divided using electronic program into two groups: The first group will receive intraoperative local Liposomal Bupivacaine injection at the port placement site. The control group will receive will local Marcaine (bupivacaine HCl) injection Primary Outcome Measures: - Total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital Stay - Postoperative pain assessment using visual Analog Pain Scores & Brief Pain Inventory form. - Length of Hospital Stay - Time to First Opioid Use. - Postoperative Constipation , paralytic ileus


Criteria:

Inclusion Criteria: - Patients undergoing urologic surgery. Exclusion Criteria: - Pregnant and/or nursing mothers. - Allergy to bupivacaine. - History of drug/alcohol abuse. - Severe cardiovascular, hepatic, renal disease or neurological impairment.


NCT ID:

NCT02805504


Primary Contact:

Study Director
Mohamed Keheila, MD
Loma Linda University Medical Center

Mohamed Keheila, MD
Phone: 909 558 4196 ext. 44196
Email: mkeheila@llu.edu


Backup Contact:

N/A


Location Contact:

Loma Linda, California 92350
United States

Mohamed Keheila

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.